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Technology has been used to improve our food supply since primitive man first
cultivated crops such as wheat and barley in Mesopotamia in 6,000 BC and
domesticated animals such as sheep and goats in southwestern Asia over 10,000
years ago. Recently, improvement of our food supply has been achieved by the
development of hybrids, notably of corn, and by breeding and selection which
more than doubled wheat and rice crops in developing countries in the 1960s
and 1970s (the “green revolution”). Breeding and selection has also increased
the supply of domesticated animal species that are sources of foods; for
example, chicken, one of the more expensive meats in the 1940s, is now one
of␣ the least expensive. Selection of certain traits in plants and animals did not
occur without change, not only in the plant and animal species involved, but
also in society.
What differentiates the so-called old technology described above from the
new technology is genetic engineering, also referred to as molecular breeding.
This technology facilitates the selection, identification, and transfer of genes
encoding for specific proteins into the genome of another species. Molecular
breeding precisely determines which proteins are introduced, where they are
expressed and, in some cases, requires synthesis of only minute amounts of
a␣ protein in order to obtain the desired trait. Supporters of this technology
believe that it will provide substantial benefits for mankind such as less
expensive and healthier foods, foods that will help to eliminate diseases and
aid␣ in feeding the growing world population. Already, crops genetically
modified for insect resistance are significantly reducing the use of synthetic
organic insectides in the United States. However, critics have raised concerns
regarding environmental effects, such as gene spread from genetically-modified
(GM) crops to indigenous relatives, and adverse effects on the health of
mankind. A major health concern is the development of foods of greater
allergenicity or containing novel allergens in new foods (Jacobson, 2002; Millis,
2002; NRC, 2002).
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DEVELOPMENT OF FOOD-INDUCED ALLERGIC REACTIONS
Food may be a major cause of severe acute hypersensitivity reactions, including
fatal anaphylaxis, in some individuals. Food allergy has been estimated to be
the most frequent cause of anaphylaxis treated in emergency rooms (Yocum
and␣ Khan, 1994). Severe reactions to foods can occur at all ages, from infants
(Ellis et al., 1991; Saylor and Bahna 1991) to children, adolescents, and adults
(Sampson et al., 1992). Currently, the only means of managing severe acute
food reactions is strict avoidance and the immediate availability of emergency
medications. However, accidental or inadvertent exposure to food allergens can
occur even for the most careful food-allergic patient. The unpredictability of
accidental exposures and long periods of time during which patients at risk
may not come in contact with the offending foods make it difficult to have
medications available at all times, as is necessary to prevent a fatal reaction
(Yunginger et al., 1988; Sampson et al., 1992).
The vast majority of acute, severe reactions to foods appear to be IgE-
mediated, although non-IgE-mediated reactions also occur (Hill et al., 1995).
The presence of IgE antibodies as the likely cause for severe acute food
reactions suggests the possibility of changing this allergic reactivity to a less
noxious or even protective form of immune response through immunotherapy
or of altering the reactivity of major food allergens with IgE antibodies.
The induction and provocation of an IgE-mediated hypersensitivity food
allergy is summarized in Figure 1. When an individual is first exposed to a food
Figure 1. The induction and provocation of an IgE-mediated
food-allergic response.
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allergen, this molecule or a fragment thereof, crosses the mucosal barrier;
following processing and presentation by macrophages and T lymphocytes,
peptides (derived from allergens) can activate T and B lymphocytes. Interaction
between these cells results in activated B lymphocytes that produce IgE
antibodies that react specifically with the allergen that stimulated their
production. These IgE antibodies (in addition to reacting to allergens) have
the␣ unique ability to fix to the surfaces of mast cells or basophils, cells that
contain a number of potent pharmacologically active molecules called
mediators. When an allergen cross-links two or more specific IgE antibodies
bound to mast cell or basophil membranes, mediators are released that affect
both local and systemic organ systems, resulting in the clinical effects seen in
allergic reactions such as asthma, eczema, hay fever, and anaphylaxis.
GENERAL PROPERTIES OF FOOD ALLERGENS
Although allergenic foods may contain over 10,000 different proteins, only a
few (generally ten to twenty) elicit allergic reactions. The structural properties
that are responsible for the allergenicity of a food protein are generally still
poorly defined, although some broad characteristics of food allergens have been
identified. These include abundance of a given protein in a particular food;
physicochemical properties, such as acidic isoelectric point and glycosylation;
and resistance to heat and digestion (Lehrer et al., 2002). Although these
characteristics have been associated with the allergenicity of proteins, some,
if␣ not all, of these properties characterize a vast number of non-allergenic
proteins as well and, thus, are not unique to food allergens.
The portion of the allergen molecule that is recognized by, and interacts with,
allergen-specific IgE is the allergenic epitope. Most allergens, as stated above,
are resistant to heat; although heat denaturation may cause loss of the native
protein’s conformation, patients’ IgE antibodies can still react with such
denatured food proteins, suggesting that the allergens’ epitopes are not
dependent on the native conformation (Lehrer et al., 2002). Thus, alteration
of␣ these epitopes is the focus of current technology—to reduce or abolish their
reactivity with IgE, resulting in reduction of allergenicity.
Food allergens frequently account for a major fraction of the total protein
content within a given food. For example, the major shrimp allergen, Pen a 1,
accounts for about 20% of the total shrimptail-muscle protein (Daul et al.,
1994). An exception to this rule is the major allergen of codfish Gadus callarias,
Gad c 1; this molecule, identified as parvalbumin, is not a dominant protein in
cod muscle (Elsayed and Bennich, 1975). There are several aspects of molecular
size that may contribute to a protein’s allergenicity. First, the molecule must be
large enough to elicit an immune response but small enough to cross the gut
mucosal membrane barrier; second, it must be of sufficient size to contain at
least two IgE binding sites to bridge mast-cell-bound IgE.
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The ability of a food allergen to cross the mucosal membrane of the intestinal
tract is most likely an important feature. As mentioned earlier, size is one
parameter in this context; another may be a resistance to digestion. The results
of one study, which used a gastric model of mammalian digestion to study
the␣ digestibility of food allergens, point in this direction (Fuchs and Astwood,
1996): allergens from egg, milk, peanut, soybean, and mustard resisted
digestion for up to 1 hour, whereas nonallergens were digested within 1 minute.
However, there is insufficient information to conclude that the resistance to
enzymatic digestion is a property that distinguishes all food allergens from
non-allergens, since some labile proteins can be allergenic and not all stable
proteins are allergens.
PREDICTING FOOD PROTEIN ALLERGENICITY—DECISION TREE
Over the last 10 to 12 years, governmental agencies (FDA, EPA, USDA),
industry organizations (ILSI, AII, IFBC) as well as international health
organizations (FAO, WHO) have addressed the issue of the allergenicity of
GM␣ foods. Their discussions have resulted in developing a decision-making
process to aid companies and regulatory agencies in assessing the potential
allergenicity of products being developed. Theoretically, there are three
potential alterations that could affect the allergenicity of a GM food. First,
endogenous protein levels could be affected and if these proteins are allergens,
this could result in enhanced allergenicity. Second, the protein whose gene is
expressed in a GM food could be a known allergen if derived from an allergenic
source. Third, novel proteins expressed from sources for which there is no
prior␣ human exposure may be allergens.
A decision process developed to address these issues (Figure 2) is based on
the source of the gene: is it from an allergenic or non-allergenic source? If it
is␣ from an allergenic source, there are solid-phase, immune assays that, with
sera from allergic individuals, can be used to determine the allergenicity of the
molecule being expressed or the enhanced levels of endogenous allergens.
If␣ the␣ expressed protein is from a source for which there has been no prior
human exposure, the assessment of its allergenicity is more difficult. This
assessment is based on a comparison of the properties of the molecule to
properties of known food allergens, such as amino acid sequence similarity,
stability to enzymatic digestion, and stability to processing. Such an approach,
while not yielding absolute definitive answers, can help in assessing the
potential allergenicity of the molecule in question (Metcalfe et al., 2000).
Clearly, as technology improves and our knowledge of food allergens increases,
better assessment methods for allergenicity of novel proteins can be expected.
Generally, the current risk assessment for allergens is reasonable, provides
assurance of food safety and has worked well in avoiding the development of
allergenic GM foods. Although risk assessment for known allergens is well
delineated, risk assessment for novel proteins is more problematic and needs
to␣ be improved as our knowledge of food allergens increases.
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USE OF BIOTECHNOLOGY TO DEVELOP HYPOALLERGENIC FOODS AND
SAFER ALLERGENIC VACCINES
Genetic modification of plants and animals, may, in the future, improve the
safety and quality of foods, by reducing allergenicity of known allergens.
A␣ number of major allergens have been identified in agronomically important
crops such as soy and wheat as well as in less economically important crops
such as peanut and tree nuts. Furthermore, important allergens have been
demonstrated in a variety of animal products used for food, such as milk, eggs,
fish and particularly shellfish (Bush and Hefle, 1996).
There are several approaches to reduce allergens in food. Traditional plant
breeding has been used to identify strains with reduced allergenic activity.
Food-processing methods have also been used in attempts to reduce or
eliminate the allergenicity of various food products. Most recently, genetic
engineering has been employed:
Figure 2. Assessment of the allergenic potential of foods derived from
genetically engineered crops—International Life Sciences Institute (ILSI)
decision tree.
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• post-transcriptional silencing to decrease the level of protein synthesized
in a particular food;
• reduction of disulfide bonds to alter the structure of allergens to reduce
their allergenicity;
• modification of genes encoding allergens.
For gene modification, extensive knowledge of allergen structure is needed,
including amino acid sequences, as is gene-nucleotide sequence. Furthermore,
the IgE binding sites—the portion of the allergen that actually binds IgE and
is␣ responsible for allergic reactions—must be determined (Bannon, in press).
Shrimp and peanuts are two foods that have been extensively investigated
since they can induce severe anaphylactic reactions in sensitized children and
adults that can result in death. The only major allergen in shrimp is the heat-
stable muscle protein, tropomyosin, called Pen a 1 in Penaus azectus, which is
studied in our laboratory. Tropomyosin has a rather intriguing, highly stable
structure: a coiled coil composed of two identical tropomyosin polypeptide
chains in alpha-helix formation coiled around each other. Using overlapping
peptides, five major IgE-binding regions were identified in the tropomyosin
molecule. Further analysis of these regions by overlapping peptides of shorter
length identified the minimal sequence that binds IgE from sera of shrimp-
allergic subjects. Individually recognized epitopes of region 5 are shown in
Figure 3.
Figure 3. Shrimp tropomyosin epitopes 5a, 5b and 5c in IgE-binding region 5.
Region 5 is composed of three individual IgE binding epitopes (Lehrer et al.,
2002). A total of eight epitopes were identified in the five IgE binding regions.
The epitope amino acid sequence, as defined by maximal IgE antibody
reactivity, varies for some epitopes (i.e. epitope 3a) whereas is essentially
identical for others (i.e. 5b). Alteration of these peptide epitopes by amino-acid
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substitution was performed based on homologous amino acid sequences in
other tropomyosin molecules (Figure 4). A number of amino-acid substitutions
were demonstrated that completely abolished IgE antibody binding. These
results are very encouraging since these amino-acid substitutions should not
alter the structure of the protein molecule yet substantially abolish its
allergenicity.
Figure 4. Amino-acid substitutions in epitope 5c that alter IgE binding.
Advances have also been achieved using a similar approach to modify peanut
allergens. Three major peanut allergens have been identified: Ara h 1, Ara h 2,
and Ara h 3 (Burks et al., 1991, 1992; Eigenman et al., 1996). Four other
proteins have been identified as peanut allergens and designated Ara h 4–7.
With the exception of Ara h 5, they all show significant homology with either
Ara h 1, 2, or 3 (Kleber-Janke et al., 1999). Ara h 5 is a member of the profilin
family, but is only recognized by IgE from a small fraction (13%) of the peanut
allergic population (Kleber-Janke et al., 1999). As discussed for shrimp
tropomyosin, the linear IgE-binding epitopes for the major peanut allergens
were mapped using overlapping peptides and serum IgE from patients with
documented peanut hypersensitivity. Twenty-one different linear IgE binding
epitopes were identified throughout the length of the Ara h 1 molecule (Burks
et al., 1997). Ten IgE-binding epitopes were identified in Ara h 2 and 4 in Ara h
3 using the same methods (Stanley et al., 1997; Rabjohn et al., 1999). The
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epitopes ranged in length from six to fifteen amino acids, but no obvious
sequence motif was shared by all peptides. Four of the Ara h 1 epitopes
appeared to be immunodominant IgE-binding peptides in that they were
recognized by serum from more than 80% of the patients tested and bound
more IgE than any of the other Ara h 1 IgE-binding epitopes. Similarly, three
of␣ the Ara h 2 IgE-binding epitopes and one of the Ara h 3 epitopes were
determined to be immunodominant.
Each of the IgE-binding epitopes for the three major peanut allergens was
subjected to site-directed mutational analysis. Single amino acid changes
within␣ these peptides had dramatic effects on IgE-binding characteristics.
One␣ or more amino acids within each epitope were found to be critical for IgE
binding. Substitution of one of these critical amino acids led to loss of most
of␣ the IgE binding (Burks et al., 1997; Shin et al., 1998; Stanley et al., 1997).
Analysis of the type and position of amino acids within the IgE-binding
epitopes that had this effect indicated that substitution of hydrophobic residues
in the center of the epitopes was likely to lead to loss of IgE binding (Shin et al.,
1998). These results have been used to develop recombinant forms of these
allergens for use in immunotherapy. The engineered hypoallergenic peanut
protein variants display two characteristics essential for recombinant allergen
immunotherapy: they have a reduced binding capacity for serum IgE from
peanut-hypersensitive patients and they stimulate T-cell proliferation and
activation (Bannon et al., 2001; Rabjohn et al., 2002; Bannon, in press).
CONCLUSION
The studies reviewed are representative of investigations using genetic
modification to alter allergenicity of food proteins. In spite of the initial success
of such studies, significant challenges remain. The simultaneous expression
of␣ modified allergen genes with repression of wild-type allergen genes needs to
be further developed, particularly in animal species. It is important that any
altered allergens developed be demonstrated not to contain potentially new
allergenic epitopes. Only further studies over time can delineate this. However,
in spite of these issues, the impact of biotechnology on the future production
of␣ hypoallergenic foods appears to be bright.
The discovery and characterization of existing food allergens and their
genes␣ has occurred at a very rapid rate due primarily to progress in technology.
In addition, numerous methods are being developed for enhancing allergy-
diagnostic technologies and allergen therapy. One of these approaches is the
development of hypoallergenic foods. It is to be hoped that, in the not too
distant future, foods will be developed that will substantially reduce the
number and severity of allergic reactions for already sensitized subjects while
reducing sensitization of others. In addition, extracts of these foods will be
important in developing safer vaccines for future treatment of food-allergic
subjects.
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